{{Use dmy dates|date=July 2011}}

{{PBB|geneid=596}}
'''Bcl-2''' ('''B-cell lymphoma 2'''), encoded by the '''BCL2''' [[gene]], is the founding member of the [[apoptosis regulator proteins, Bcl-2 family|Bcl-2 family]] of [[regulator protein]]s that regulate cell death ([[apoptosis]]).<ref name="pmid6093263">{{cite journal | author = Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM | title = Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation | journal = Science | volume = 226 | issue = 4678 | pages = 1097–99| year = 1984 | month = November | pmid = 6093263 | doi = 10.1126/science.6093263| url =  }}</ref><ref name="pmid2875799">{{cite journal | author = Cleary ML, Smith SD, Sklar J | title = Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation | journal = Cell | volume = 47 | issue = 1 | pages = 19–28 | year = 1986 | month = October | pmid = 2875799 | doi =10.1016/0092-8674(86)90362-4| url =  }}</ref> 

Bcl-2 derives its name from ''B-cell lymphoma 2'', as it is the second member of a range of proteins initially described in [[chromosomal translocation]]s involving [[chromosome]]s 14 and 18 in [[follicular lymphoma]]s. ''Bcl-2'' [[orthologs]]<ref name="OrthoMaM">{{cite web | title = OrthoMaM phylogenetic marker: Bcl-2 coding sequence | url = http://www.orthomam.univ-montp2.fr/orthomam/data/cds/detailMarkers/ENSG00000171791_BCL2.xml }}</ref> have been identified in numerous [[mammals]] for which complete [[genome]] data are available. The two [[isoforms]] of Bcl-2, Isoform 1, also known as 1G5M, and Isoform 2, also known as 1G5O/1GJH, exhibit similar fold. However, results in the ability of these isoforms to bind to the [[Bcl-2-associated death promoter|BAD]] and [[Bcl-2 homologous antagonist killer | BAK]] proteins, as well as in the structural topology and [[electrostatic potential]] of the binding groove, suggest differences in antiapoptotic activity for the two [[Protein isoform|isoforms]] <ref name="Human Bcl2 1G5M">{{cite web | title = Human Bcl2, Isoform 1 | url = http://www.rcsb.org/pdb/explore/explore.do?structureId=1G5M }}</ref>

== Role in disease ==

Damage to the Bcl-2 gene has been identified as a cause of a number of [[cancer]]s, including [[melanoma]], [[breast cancer|breast]], [[prostate cancer|prostate]], [[chronic lymphocytic leukemia]], and [[lung cancer]], and a possible cause of [[schizophrenia]] and [[autoimmunity]]. It is also a cause of resistance to cancer treatments. 

Cancer occurs as the result of a disturbance in the [[homeostatic]] balance between cell growth and cell death.  Over-expression of anti-apoptotic genes, and under-expresion of pro-apoptotic genes, can result in the lack of cell death that is characteristic of cancer. An example can be seen in [[lymphoma]]s.  The over-expression of the anti-apoptotic Bcl-2 protein in lymphocytes alone does not cause cancer.  But simultaneous over-expression of Bcl-2 and the proto-oncogene [[myc]] may produce aggressive [[B-cell]] malignancies including lymphoma.<ref name="pmid17179226">{{cite journal | author = Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ | title = Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA | journal = Blood | volume = 109 | issue = 7 | pages = 3069–75 | year = 2007 | month = April | pmid = 17179226 | pmc = 1852223 | doi = 10.1182/blood-2006-08-043257 | url =  }}</ref>
In [[follicular lymphoma]], a [[chromosomal translocation]] commonly occurs between the fourteenth and the eighteenth [[chromosome]]s—t(14;18) — which places the Bcl-2 gene next to the [[immunoglobulin]] heavy chain locus. This fusion gene is deregulated, leading to the transcription of excessively high levels of Bcl-2.<ref name="pmid3262202">{{cite journal | author = Vaux DL, Cory S, Adams JM | title = Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells | journal = Nature | volume = 335 | issue = 6189 | pages = 440–2 | year = 1988 | month = September | pmid = 3262202 | doi = 10.1038/335440a0 | url =  }}</ref> This decreases the propensity of these cells for undergoing apoptosis.

Apoptosis also plays a very active role in regulating the immune system.  When it is functional, it can cause immune unresponsiveness to self-antigens via both central and peripheral tolerance.  In the case of defective apoptosis, it may contribute to etiological aspects of autoimmune diseases.<ref name="pmid17162368">{{cite journal | author = Li A, Ojogho O, Escher A | title = Saving death: apoptosis for intervention in transplantation and autoimmunity | journal = Clin. Dev. Immunol. | volume = 13 | issue = 2–4 | pages = 273–82 | year = 2006 | pmid = 17162368 | pmc = 2270759 | doi = 10.1080/17402520600834704 | url =  }}</ref> The autoimmune disease, type 1 diabetes can be caused by defective apoptosis, which leads to aberrant T cell AICD and defective peripheral tolerance.  Due to the fact that [[dendritic cell]]s are the most important [[antigen presenting cell]]s of the immune system, their activity must be tightly regulated by such mechanisms as apoptosis.  Researchers have found that mice containing dendritic cells that are [[BCL2L11|Bim]] -/-, thus unable to induce effective apoptosis, obtain autoimmune diseases more so than those that have normal dendritic cells.<ref name="pmid17162368"/> Other studies have shown that the lifespan of dendritic cells may be partly controlled by a timer dependent on anti-apoptotic Bcl-2.<ref name="pmid17162368"/> 

Apoptosis plays a very important role in regulating a variety of diseases that have enormous social impacts. For example, schizophrenia is a [[neurodegenerative disease]] that may result from an abnormal ratio of pro- and anti-apoptotic factors.<ref name="pmid16226876">{{cite journal | author = Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF | title = Apoptotic mechanisms and the synaptic pathology of schizophrenia | journal = Schizophr. Res. | volume = 81 | issue = 1 | pages = 47–63 | year = 2006 | month = January | pmid = 16226876 | doi = 10.1016/j.schres.2005.08.014 | url =  }}</ref> There is some evidence that this defective apoptosis may result from abnormal expression of Bcl-2 and increased expression of caspase-3.<ref name="pmid16226876"/>

Further research into the family of Bcl-2 proteins will provide a more complete picture on how these proteins interact with each other to promote and inhibit apoptosis{{citation needed|date=November 2011}}. An understanding of the mechanisms involved may help develop new therapies for treating cancer, autoimmune conditions, and neurological diseases.

===Diagnostic use===
Antibodies to Bcl-2 can be used with [[immunohistochemistry]] to identify cells containing the antigen. In healthy tissue, these antibodies will react with B-cells in the [[mantle zone]], as well as some [[T-cell]]s. However, there is a considerable increase in positive cells in [[follicular lymphoma]], as well as many other forms of cancer. In some cases, the presence or absence of Bcl-2 staining in [[biopsy|biopsies]] may be significant for the patient's [[prognosis]] or likelihood of [[relapse]].<ref name=Leong>{{cite book|author=Leong, Anthony S-Y|author2=Cooper, Kumarason|author3=Leong, F Joel W-M|year=2003|title=Manual of Diagnostic Cytology|edition=2|publisher=Greenwich Medical Media, Ltd.|pages=XX|isbn=1-84110-100-1}}</ref>

==Targeted therapies==

[[Bcl-2 inhibitor]]s include :

===Genasense===
An antisense [[oligonucleotide]] drug [[Genasense]] (G3139) has been developed by [[Genta (company)|Genta Incorporated]] to target Bcl-2. An [[antisense]] DNA or RNA strand is non-coding and complementary to the coding strand (which is the template for producing respectively RNA or protein). An [[antisense drugs|antisense drug]] is a short sequence of RNA that hybridises with and inactivates mRNA, preventing the protein from being formed.

It was shown that the proliferation of human [[lymphoma]] [[cell (biology)|cells]] (with t(14;18) translocation) could be inhibited by antisense RNA targeted at the start [[codon]] region of Bcl-2 [[mRNA]]. [[In vitro]] studies led to the identification of Genasense, which is complementary to the first 6 codons of Bcl-2 mRNA.<ref name="pmid12445555">{{cite journal | author = Dias N, Stein CA | title = Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides | journal = Eur J Pharm Biopharm | volume = 54 | issue = 3 | pages = 263–9 | year = 2002 | month = November | pmid = 12445555 | doi = 10.1016/S0939-6411(02)00060-7| url = http://linkinghub.elsevier.com/retrieve/pii/S0939641102000607 }}</ref>

These have shown successful results in Phase I/II trials for lymphoma, and a large Phase III trial was launched in 2004<ref name="pmid15010151">{{cite journal | author = Mavromatis BH, Cheson BD | title = Novel therapies for chronic lymphocytic leukemia | journal = Blood Rev. | volume = 18 | issue = 2 | pages = 137–48 | year = 2004 | month = June | pmid = 15010151 | doi = 10.1016/S0268-960X(03)00039-0 | url =  }}</ref>

By the first quarter 2010, Genasense had not received [[Food and Drug Administration|FDA]] approval due to disappointing results in a melanoma trial. Although safety and efficacy of Genasense have not been established for any use, Genta Incorporated still claims on its website that studies are currently underway to examine the potential role of Genasense in a variety of clinical indications.

===ABT-737===
[[Abbott Laboratories]] described in the mid-2000s a novel inhibitor of Bcl-2, Bcl-xL and Bcl-w, known as [[ABT-737]].<ref name="pmid15902208">{{cite journal | author = Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH | title = An inhibitor of Bcl-2 family proteins induces regression of solid tumours | journal = Nature | volume = 435 | issue = 7042 | pages = 677–81 | year = 2005 | month = June | pmid = 15902208 | doi = 10.1038/nature03579 | url =  }}</ref>  ABT-737 is one among many so-called BH3 mimetic small molecule inhibitors (SMI) targeting Bcl-2 and Bcl-2-related proteins such as Bcl-xL and Bcl-w but not A1 and [[Mcl-1]], which may prove valuable in the therapy of lymphoma and other blood cancers.<ref name="pmid15797997">{{cite journal | author = Reed JC, Pellecchia M | title = Apoptosis-based therapies for hematologic malignancies | journal = Blood | volume = 106 | issue = 2 | pages = 408–18 | year = 2005 | month = July | pmid = 15797997 | doi = 10.1182/blood-2004-07-2761 | url =  }}</ref>

===ABT-199===
A Phase Ia trial is currently ongoing to study the effects of agent, ABT-199, a so-called BH3-mimetic drug designed to block the function of the Bcl-2 protein, on patients with [[chronic lymphocytic leukemia]]. <ref>http://www.asianscientist.com/tech-pharma/abt-199-bh-3-mimetic-wehi-phase-ia-trial-chronic-lymphocytic-leukemia/</ref>

January 17, 2013
The study had suspended participant recruitment per a temporary hold <ref>http://clinicaltrials.gov/show/NCT01328626</ref>

===Others===
*[[obatoclax]] (GX15-070) has phase II results for [[small-cell lung cancer]].<ref>http://www.genengnews.com/gen-news-highlights/cephalon-to-spend-225m-to-purchase-gemin-x-for-phase-ii-sclc-candidate/81244855/</ref>

==Interactions==
[[Image:Signal transduction pathways.svg|thumb|right|Overview of signal transduction pathways involved in [[apoptosis]].]]
Bcl-2 has been shown to [[Protein-protein interaction|interact]] with [[RAD9A]],<ref name=pmid10620799>{{cite journal |last=Komatsu |first=K |authorlink= |coauthors=Miyashita T, Hang H, Hopkins K M, Zheng W, Cuddeback S, Yamada M, Lieberman H B, Wang H G |year=2000|month=Jan. |title=Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis |journal=Nat. Cell Biol. |volume=2 |issue=1 |pages=1–6 |publisher= |location = ENGLAND| issn = 1465-7392| pmid = 10620799 |doi = 10.1038/71316 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BAK1]],<ref name=pmid14980220>{{cite journal |doi=10.1016/S0092-8674(04)00162-X |last=Lin |first=Bingzhen |authorlink= |coauthors=Kolluri Siva Kumar, Lin Feng, Liu Wen, Han Young-Hoon, Cao Xihua, Dawson Marcia I, Reed John C, Zhang Xiao-kun |year=2004|month=Feb. |title=Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3 |journal=Cell |volume=116 |issue=4 |pages=527–40 |publisher= |location = United States| issn = 0092-8674| pmid = 14980220 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid11728179>{{cite journal |doi=10.1021/jm010016f |last=Enyedy |first=I J |authorlink= |coauthors=Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long Y Q, Roller P P, Yang D, Wang S |year=2001|month=Dec. |title=Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening |journal=J. Med. Chem. |volume=44 |issue=25 |pages=4313–24 |publisher= |location = United States| issn = 0022-2623| pmid = 11728179 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Reticulon 4]],<ref name=pmid11126360>{{cite journal |last=Tagami |first=S |authorlink= |coauthors=Eguchi Y, Kinoshita M, Takeda M, Tsujimoto Y |year=2000|month=Nov. |title=A novel protein, RTN-XS, interacts with both Bcl-XL and Bcl-2 on endoplasmic reticulum and reduces their anti-apoptotic activity |journal=Oncogene |volume=19 |issue=50 |pages=5736–46 |publisher= |location = England| issn = 0950-9232| pmid = 11126360 |doi = 10.1038/sj.onc.1203948 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Bcl-2-associated X protein]],<ref name=pmid10620799/><ref name=pmid14980220/><ref name=pmid15231068>{{cite journal |last=Hoetelmans |first=R W M |authorlink= |year=2004|month=Jun. |title=Nuclear partners of Bcl-2: Bax and PML |journal=DNA Cell Biol. |volume=23 |issue=6 |pages=351–4 |publisher= |location = United States| issn = 1044-5498| pmid = 15231068 |doi = 10.1089/104454904323145236 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid8358790>{{cite journal |doi=10.1016/0092-8674(93)90509-O |last=Oltvai |first=Z N |authorlink= |coauthors=Milliman C L, Korsmeyer S J |year=1993|month=Aug. |title=Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death |journal=Cell |volume=74 |issue=4 |pages=609–19 |publisher= |location = UNITED STATES| issn = 0092-8674| pmid = 8358790 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Caspase 8]],<ref name=pmid11406564>{{cite journal |last=Poulaki |first=V |authorlink= |coauthors=Mitsiades N, Romero M E, Tsokos M |year=2001|month=Jun. |title=Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2 |journal=Cancer Res. |volume=61 |issue=12 |pages=4864–72 |publisher= |location = United States| issn = 0008-5472| pmid = 11406564 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid11832478>{{cite journal |last=Guo |first=Yin |authorlink= |coauthors=Srinivasula Srinivasa M, Druilhe Anne, Fernandes-Alnemri Teresa, Alnemri Emad S |year=2002|month=Apr. |title=Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria |journal=J. Biol. Chem. |volume=277 |issue=16 |pages=13430–7 |publisher= |location = United States| issn = 0021-9258| pmid = 11832478 |doi = 10.1074/jbc.M108029200 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BECN1]],<ref name=pmid9765397>{{cite journal |last=Liang |first=X H |authorlink= |coauthors=Kleeman L K, Jiang H H, Gordon G, Goldman J E, Berry G, Herman B, Levine B |year=1998|month=Nov. |title=Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein |journal=J. Virol. |volume=72 |issue=11 |pages=8586–96 |publisher= |location = UNITED STATES| issn = 0022-538X| pmid = 9765397 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=110269 }}</ref> [[SOD1]],<ref name=pmid15233914>{{cite journal |last=Pasinelli |first=Piera |authorlink= |coauthors=Belford Mary Elizabeth, Lennon Niall, Bacskai Brian J, Hyman Bradley T, Trotti Davide, Brown Robert H |year=2004|month=Jul. |title=Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria |journal=Neuron |volume=43 |issue=1 |pages=19–30 |publisher= |location = United States| issn = 0896-6273| pmid = 15233914 |doi = 10.1016/j.neuron.2004.06.021 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Bcl-2-interacting killer]],<ref name=pmid15694340>{{cite journal |last=Chen |first=Lin |authorlink= |coauthors=Willis Simon N, Wei Andrew, Smith Brian J, Fletcher Jamie I, Hinds Mark G, Colman Peter M, Day Catherine L, Adams Jerry M, Huang David C S |year=2005|month=Feb. |title=Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function |journal=Mol. Cell |volume=17 |issue=3 |pages=393–403 |publisher= |location = United States| issn = 1097-2765| pmid = 15694340 |doi = 10.1016/j.molcel.2004.12.030 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid12853473>{{cite journal |last=Gillissen |first=Bernhard |authorlink= |coauthors=Essmann Frank, Graupner Vilma, Stärck Lilian, Radetzki Silke, Dörken Bernd, Schulze-Osthoff Klaus, Daniel Peter T |year=2003|month=Jul. |title=Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway |journal=EMBO J. |volume=22 |issue=14 |pages=3580–90 |publisher= |location = England| issn = 0261-4189| pmid = 12853473 |doi = 10.1093/emboj/cdg343 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=165613 }}</ref> [[BH3 interacting domain death agonist]],<ref name=pmid15694340/><ref name=pmid15520201>{{cite journal |last=Real |first=Pedro Jose |authorlink= |coauthors=Cao Yeyu, Wang Renxiao, Nikolovska-Coleska Zaneta, Sanz-Ortiz Jaime, Wang Shaomeng, Fernandez-Luna Jose Luis |year=2004|month=Nov. |title=Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of Bcl-2 |journal=Cancer Res. |volume=64 |issue=21 |pages=7947–53 |publisher= |location = United States| issn = 0008-5472| pmid = 15520201 |doi = 10.1158/0008-5472.CAN-04-0945 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[RRAS]],<ref name=pmid8232588>{{cite journal |last=Fernandez-Sarabia |first=M J |authorlink= |coauthors=Bischoff J R |year=1993|month=Nov. |title=Bcl-2 associates with the ras-related protein R-ras p23 |journal=[[Nature (journal)|Nature]] |volume=366 |issue=6452 |pages=274–5 |publisher= |location = ENGLAND| issn = 0028-0836| pmid = 8232588 |doi = 10.1038/366274a0 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[C-Raf]],<ref name=pmid8929532>{{cite journal |doi=10.1016/S0092-8674(00)81383-5 |last=Wang |first=H G |authorlink= |coauthors=Rapp U R, Reed J C |year=1996|month=Nov. |title=Bcl-2 targets the protein kinase Raf-1 to mitochondria |journal=Cell |volume=87 |issue=4 |pages=629–38 |publisher= |location = UNITED STATES| issn = 0092-8674| pmid = 8929532 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BCL2L11]],<ref name=pmid15694340/><ref name=pmid9430630>{{cite journal |last=O'Connor |first=L |authorlink= |coauthors=Strasser A, O'Reilly L A, Hausmann G, Adams J M, Cory S, Huang D C |year=1998|month=Jan. |title=Bim: a novel member of the Bcl-2 family that promotes apoptosis |journal=EMBO J. |volume=17 |issue=2 |pages=384–95 |publisher= |location = ENGLAND| issn = 0261-4189| pmid = 9430630 |doi = 10.1093/emboj/17.2.384 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=1170389 }}</ref><ref name=pmid9731710>{{cite journal |doi=10.1210/me.12.9.1432 |last=Hsu |first=S Y |authorlink= |coauthors=Lin P, Hsueh A J |year=1998|month=Sep. |title=BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members |journal=Mol. Endocrinol. |volume=12 |issue=9 |pages=1432–40 |publisher= |location = UNITED STATES| issn = 0888-8809| pmid = 9731710 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BNIPL]],<ref name=pmid12901880>{{cite journal |doi=10.1016/S0006-291X(03)01387-1 |last=Qin |first=Wenxin |authorlink= |coauthors=Hu Jian, Guo Minglei, Xu Jian, Li Jinjun, Yao Genfu, Zhou Xiaomei, Jiang Huiqiu, Zhang Pingping, Shen Li, Wan Dafang, Gu Jianren |year=2003|month=Aug. |title=BNIPL-2, a novel homologue of BNIP-2, interacts with Bcl-2 and Cdc42GAP in apoptosis |journal=Biochem. Biophys. Res. Commun. |volume=308 |issue=2 |pages=379–85 |publisher= |location = United States| issn = 0006-291X| pmid = 12901880 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref><ref name=pmid9973195>{{cite journal |last=Yasuda |first=M |authorlink= |coauthors=Han J W, Dionne C A, Boyd J M, Chinnadurai G |year=1999|month=Feb. |title=BNIP3alpha: a human homolog of mitochondrial proapoptotic protein BNIP3 |journal=Cancer Res. |volume=59 |issue=3 |pages=533–7 |publisher= |location = UNITED STATES| issn = 0008-5472| pmid = 9973195 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[HRK (gene)|HRK]],<ref name=pmid15694340/><ref name=pmid9130713>{{cite journal |last=Inohara |first=N |authorlink= |coauthors=Ding L, Chen S, Núñez G |year=1997|month=Apr. |title=harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L) |journal=EMBO J. |volume=16 |issue=7 |pages=1686–94 |publisher= |location = ENGLAND| issn = 0261-4189| pmid = 9130713 |doi = 10.1093/emboj/16.7.1686 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=1169772 }}</ref> [[PSEN1]],<ref name=pmid10521466>{{cite journal |doi=10.1074/jbc.274.43.30764 |last=Alberici |first=A |authorlink= |coauthors=Moratto D, Benussi L, Gasparini L, Ghidoni R, Gatta L B, Finazzi D, Frisoni G B, Trabucchi M, Growdon J H, Nitsch R M, Binetti G |year=1999|month=Oct. |title=Presenilin 1 protein directly interacts with Bcl-2 |journal=J. Biol. Chem. |volume=274 |issue=43 |pages=30764–9 |publisher= |location = UNITED STATES| issn = 0021-9258| pmid = 10521466 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BMF (gene)|BMF]],<ref name=pmid11546872>{{cite journal |last=Puthalakath |first=H |authorlink= |coauthors=Villunger A, O'Reilly L A, Beaumont J G, Coultas L, Cheney R E, Huang D C, Strasser A |year=2001|month=Sep. |title=Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis |journal=[[Science (journal)|Science]] |volume=293 |issue=5536 |pages=1829–32 |publisher= |location = United States| issn = 0036-8075| pmid = 11546872 |doi = 10.1126/science.1062257 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BNIP2]],<ref name=pmid12901880/><ref name=pmid7954800>{{cite journal |doi=10.1016/0092-8674(94)90202-X |last=Boyd |first=J M |authorlink= |coauthors=Malstrom S, Subramanian T, Venkatesh L K, Schaeper U, Elangovan B, D'Sa-Eipper C, Chinnadurai G |year=1994|month=Oct. |title=Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins |journal=Cell |volume=79 |issue=2 |pages=341–51 |publisher= |location = UNITED STATES| issn = 0092-8674| pmid = 7954800 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BNIP3]],<ref name=pmid7954800/><ref name=pmid10625696>{{cite journal |doi=10.1074/jbc.275.2.1439 |last=Ray |first=R |authorlink= |coauthors=Chen G, Vande Velde C, Cizeau J, Park J H, Reed J C, Gietz R D, Greenberg A H |year=2000|month=Jan. |title=BNIP3 heterodimerizes with Bcl-2/Bcl-X(L) and induces cell death independent of a Bcl-2 homology 3 (BH3) domain at both mitochondrial and nonmitochondrial sites |journal=J. Biol. Chem. |volume=275 |issue=2 |pages=1439–48 |publisher= |location = UNITED STATES| issn = 0021-9258| pmid = 10625696 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Nerve Growth factor IB]],<ref name=pmid14980220/> [[BCL2-like 1 (gene)|BCL2-like 1]],<ref name=pmid14980220/><ref name=pmid12137781>{{cite journal |doi=10.1016/S0003-2697(02)00028-3 |last=Zhang |first=Haichao |authorlink= |coauthors=Nimmer Paul, Rosenberg Saul H, Ng Shi-Chung, Joseph Mary |year=2002|month=Aug. |title=Development of a high-throughput fluorescence polarization assay for Bcl-x(L) |journal=Anal. Biochem. |volume=307 |issue=1 |pages=70–5 |publisher= |location = United States| issn = 0003-2697| pmid = 12137781 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Myc]],<ref name=pmid15210690>{{cite journal |last=Jin |first=Zhaohui |authorlink= |coauthors=Gao Fengqin, Flagg Tammy, Deng Xingming |year=2004|month=Sep. |title=Tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone promotes functional cooperation of Bcl2 and c-Myc through phosphorylation in regulating cell survival and proliferation |journal=J. Biol. Chem. |volume=279 |issue=38 |pages=40209–19 |publisher= |location = United States| issn = 0021-9258| pmid = 15210690 |doi = 10.1074/jbc.M404056200 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[BCAP31]],<ref name=pmid9334338>{{cite journal |doi=10.1083/jcb.139.2.327 |last=Ng |first=F W |authorlink= |coauthors=Nguyen M, Kwan T, Branton P E, Nicholson D W, Cromlish J A, Shore G C |year=1997|month=Oct. |title=p28 Bap31, a Bcl-2/Bcl-XL- and procaspase-8-associated protein in the endoplasmic reticulum |journal=J. Cell Biol. |volume=139 |issue=2 |pages=327–38 |publisher= |location = UNITED STATES| issn = 0021-9525| pmid = 9334338 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=2139787 }}</ref> [[SMN1]],<ref name=pmid9389483>{{cite journal |last=Iwahashi |first=H |authorlink= |coauthors=Eguchi Y, Yasuhara N, Hanafusa T, Matsuzawa Y, Tsujimoto Y |year=1997|month=Nov. |title=Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy |journal=[[Nature (journal)|Nature]] |volume=390 |issue=6658 |pages=413–7 |publisher= |location = ENGLAND| issn = 0028-0836| pmid = 9389483 |doi = 10.1038/37144 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[CAPN2]],<ref name=pmid12000759>{{cite journal |last=Gil-Parrado |first=Shirley |authorlink= |coauthors=Fernández-Montalván Amaury, Assfalg-Machleidt Irmgard, Popp Oliver, Bestvater Felix, Holloschi Andreas, Knoch Tobias A, Auerswald Ennes A, Welsh Katherine, Reed John C, Fritz Hans, Fuentes-Prior Pablo, Spiess Eberhard, Salvesen Guy S, Machleidt Werner |year=2002|month=Jul. |title=Ionomycin-activated calpain triggers apoptosis. A probable role for Bcl-2 family members |journal=J. Biol. Chem. |volume=277 |issue=30 |pages=27217–26 |publisher= |location = United States| issn = 0021-9258| pmid = 12000759 |doi = 10.1074/jbc.M202945200 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[PPP2CA]],<ref name=pmid9852076>{{cite journal |doi=10.1074/jbc.273.51.34157 |last=Deng |first=X |authorlink= |coauthors=Ito T, Carr B, Mumby M, May W S |year=1998|month=Dec. |title=Reversible phosphorylation of Bcl2 following interleukin 3 or bryostatin 1 is mediated by direct interaction with protein phosphatase 2A |journal=J. Biol. Chem. |volume=273 |issue=51 |pages=34157–63 |publisher= |location = UNITED STATES| issn = 0021-9258| pmid = 9852076 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Noxa]],<ref name=pmid15694340/><ref name=pmid10807576>{{cite journal |doi=10.1126/science.288.5468.1053 |last=Oda |first=E |authorlink= |coauthors=Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N |year=2000|month=May. |title=Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis |journal=[[Science (journal)|Science]] |volume=288 |issue=5468 |pages=1053–8 |publisher= |location = UNITED STATES| issn = 0036-8075| pmid = 10807576 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> [[Cdk1]],<ref name=pmid11774038>{{cite journal |last=Pathan |first=N |authorlink= |coauthors=Aime-Sempe C, Kitada S, Basu A, Haldar S, Reed J C |year=2001|month= |title=Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1 |journal=Neoplasia |volume=3 |issue=6 |pages=550–9 |publisher= |location = United States| issn = 1522-8002| pmid = 11774038 |doi = 10.1038/sj/neo/7900213 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=1506558 }}</ref><ref name=pmid11326318>{{cite journal |last=Pathan |first=N |authorlink= |coauthors=Aime-Sempe C, Kitada S, Haldar S, Reed J C |year=2001|month= |title=Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1 |journal=Neoplasia |volume=3 |issue=1 |pages=70–9 |publisher= |location = United States| issn = 1522-8002| pmid = 11326318 |doi = 10.1038/sj/neo/7900131 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=1505024 }}</ref> [[TP53BP2]],<ref name=pmid8668206>{{cite journal |last=Naumovski |first=L |authorlink= |coauthors=Cleary M L |year=1996|month=Jul. |title=The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M |journal=Mol. Cell. Biol. |volume=16 |issue=7 |pages=3884–92 |publisher= |location = UNITED STATES| issn = 0270-7306| pmid = 8668206 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=231385 }}</ref> [[Bcl-2-associated death promoter]]<ref name=pmid15694340/><ref name=pmid7834748>{{cite journal |doi=10.1016/0092-8674(95)90411-5 |last=Yang |first=E |authorlink= |coauthors=Zha J, Jockel J, Boise L H, Thompson C B, Korsmeyer S J |year=1995|month=Jan. |title=Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death |journal=Cell |volume=80 |issue=2 |pages=285–91 |publisher= |location = UNITED STATES| issn = 0092-8674| pmid = 7834748 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = }}</ref> and [[IRS1]].<ref name=pmid10679027>{{cite journal |last=Ueno |first=H |authorlink= |coauthors=Kondo E, Yamamoto-Honda R, Tobe K, Nakamoto T, Sasaki K, Mitani K, Furusaka A, Tanaka T, Tsujimoto Y, Kadowaki T, Hirai H |year=2000|month=Feb. |title=Association of insulin receptor substrate proteins with Bcl-2 and their effects on its phosphorylation and antiapoptotic function |journal=Mol. Biol. Cell |volume=11 |issue=2 |pages=735–46 |publisher= |location = UNITED STATES| issn = 1059-1524| pmid = 10679027 | bibcode = | oclc =| id = | url = | language = | accessdate = | laysummary = | laysource = | laydate = | quote = |pmc=14806 }}</ref>

==Human BCL-2 genes==
[[Bcl-2 homologous antagonist killer|BAK]];       [[BAK1]];      [[Bcl-2-associated X protein|BAX]];       [[BCL2]];      [[BCL2A1]];    [[BCL2L1]];    [[BCL2L10]];   [[BCL2L13]];
[[BCL2L14]];   [[BCL2L2]];    [[BCL2L7P1]];  [[BOK (gene)|BOK]];       [[MCL1]]; LGALS7 (Galectin-7)

==See also==
{{colbegin|2}}
* [[Apoptosis]]
* [[Apoptosome]]
* [[Bcl-2 homologous antagonist killer]] (BAK)
* [[Bcl-2-associated X protein]] (BAX)
* [[BH3 interacting domain death agonist]] (BID)
* [[Caspases]]
* [[Cytochrome c]]
* [[Noxa]]
* [[Mitochondrion]]
* [[Microphthalmia-associated transcription factor]]
* [[p53 upregulated modulator of apoptosis]] (PUMA)
{{colend}}

==References==
{{Reflist|2}}

==External links==
* [http://bcl2db.ibcp.fr/site/ The Bcl-2 Family Database]
* [http://www.celldeath.de/encyclo/misc/bcl2.htm The Bcl-2 Family at celldeath.de]
* [http://www.caspases.org/showpopterms.php?search=Bcl-2 Bcl-2 publications sorted by impact at caspases.org]
* {{MeshName|bcl-2+Genes}}
* {{MeshName|c-bcl-2+Proteins}}

{{Oncogenes}}
{{Fas apoptosis signaling pathway}}

<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB Controls
| update_page = yes
| require_manual_inspection = no
| update_protein_box = yes
| update_summary = no
| update_citations = no
}}

[[Category:Genes]]
[[Category:Integral membrane proteins]]
[[Category:Peripheral membrane proteins]]
[[Category:Oncology]]
[[Category:Apoptosis]]
[[Category:Programmed cell death]]